| Basics |
VistaGen Therapeutics, Inc.
VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.
|
| IPO Date: |
July 1, 2011 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$70.13M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.08 | 4.05%
|
| Avg Daily Range (30 D): |
$0.06 | 2.79%
|
| Avg Daily Range (90 D): |
$0.07 | 2.87%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.41M |
| Avg Daily Volume (30 D): |
.12M |
| Avg Daily Volume (90 D): |
.13M |
| Trade Size |
| Avg Trade Size (Sh.): |
467 |
| Avg Trade Size (Sh.) (30 D): |
211 |
| Avg Trade Size (Sh.) (90 D): |
173 |
| Institutional Trades |
| Total Inst.Trades: |
81 |
| Avg Inst. Trade: |
$2.06M |
| Avg Inst. Trade (30 D): |
$.76M |
| Avg Inst. Trade (90 D): |
$.76M |
| Avg Inst. Trade Volume: |
.13M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.82M |
| Avg Closing Trade (30 D): |
$.76M |
| Avg Closing Trade (90 D): |
$.76M |
| Avg Closing Volume: |
147.97K |
|
|
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-1.48
|
$-.46
|
$-.42
|
|
Diluted EPS
|
$-1.48
|
$-.46
|
$-.42
|
|
Revenue
|
$ .7M
|
$ .23M
|
$ .18M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -47.3M
|
$ -14.09M
|
$ -12.96M
|
|
Operating Income / Loss
|
$ -52.84M
|
$ -15.12M
|
$ -14.23M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -51.85M
|
$ -9.53M
|
$ -18.67M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jun 07, 2023:
1:30
|
|
Aug 14, 2014:
1:20
|
|
Jun 10, 2011:
2:1
|
|
